Interactions between Chloral hydrate and Dextromethorphan / phenylephrine / thonzylamine

Chloral hydrate has a major potential interaction with Acute Alcohol Intoxication.

Anxiolytic, sedative, and hypnotic agents should generally not be given to patients with acute alcohol intoxication exhibiting depressed vital signs. The central nervous system depressant effects of these agents may be additive with those of alcohol. Severe respiratory depression and death may occur. Therapy with such agents should be administered cautiously in patients who might be prone to acute alcohol intake.

Chloral hydrate has a major potential interaction with Alcoholism.

Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse. Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms. In patients who have developed tolerance, overdosage can still produce respiratory depression and death. Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible. Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents. In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients. After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.

Chloral hydrate has a moderate potential interaction with Asphyxia.

Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose. However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders. Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients. Appropriate monitoring and individualization of dosage are recommended.

The phenylephrine in dextromethorphan / phenylephrine / thonzylamine has a moderate potential interaction with Benign Prostatic Hyperplasia.

Sympathomimetic agents may cause or worsen urinary difficulty in patients with prostate enlargement due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.

The phenylephrine in dextromethorphan / phenylephrine / thonzylamine has a major potential interaction with Cardiovascular Conditions and Disorders.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

The phenylephrine in dextromethorphan / phenylephrine / thonzylamine has a major potential interaction with Cerebrovascular Insufficiency.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

Chloral hydrate has a major potential interaction with Depression.

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

The thonzylamine in dextromethorphan / phenylephrine / thonzylamine has a moderate potential interaction with Diabetes Mellitus.

Nasal decongestants that have thonzylamine should be used under physician supervision in patients with conditions such as high blood pressure, heart disease, diabetes, glaucoma, thyroid disease, and respiratory problems as emphysema or chronic bronchitis. Health care providers should outweighing the risks and the benefits of treatment in patients with these conditions.

The phenylephrine in dextromethorphan / phenylephrine / thonzylamine has a moderate potential interaction with Diabetes Mellitus.

Sympathomimetic agents may cause increases in blood glucose concentrations. These effects are usually transient and slight but may be significant with dosages higher than those normally recommended. Therapy with sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate.

Chloral hydrate has a major potential interaction with Drug Dependence.

Anxiolytic, sedative, and hypnotic agents have the potential to cause dependence and abuse. Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use of excessive dosages, and abrupt cessation and/or a reduction in dosage may precipitate withdrawal symptoms. In patients who have developed tolerance, overdosage can still produce respiratory depression and death. Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously and for as brief a period as possible. Addiction-prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance or medical supervision when treated with these agents. In addition, it may be prudent to refrain from dispensing large quantities of medication to such patients. After prolonged use or if dependency is suspected, withdrawal of medication should be undertaken gradually using a dosage-tapering schedule.

Chloral hydrate has a moderate potential interaction with Esophageal Ulceration.

Chloral hydrate may cause esophageal and gastric irritation. Oral use of chloral hydrate should be avoided in patients with esophagitis, gastritis, duodenitis, or peptic ulcer disease.

Chloral hydrate has a moderate potential interaction with Esophagitis.

Chloral hydrate may cause esophageal and gastric irritation. Oral use of chloral hydrate should be avoided in patients with esophagitis, gastritis, duodenitis, or peptic ulcer disease.

Chloral hydrate has a moderate potential interaction with Gastritis/Duodenitis.

Chloral hydrate may cause esophageal and gastric irritation. Oral use of chloral hydrate should be avoided in patients with esophagitis, gastritis, duodenitis, or peptic ulcer disease.

Chloral hydrate has a moderate potential interaction with Glaucoma/Intraocular Hypertension.

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.

The thonzylamine in dextromethorphan / phenylephrine / thonzylamine has a moderate potential interaction with Glaucoma/Intraocular Hypertension.

Nasal decongestants that have thonzylamine should be used under physician supervision in patients with conditions such as high blood pressure, heart disease, diabetes, glaucoma, thyroid disease, and respiratory problems as emphysema or chronic bronchitis. Health care providers should outweighing the risks and the benefits of treatment in patients with these conditions.

The phenylephrine in dextromethorphan / phenylephrine / thonzylamine has a moderate potential interaction with Glaucoma/Intraocular Hypertension.

Sympathomimetic agents can induce transient mydriasis via stimulation of alpha-1 adrenergic receptors. In patients with anatomically narrow angles or narrow-angle glaucoma, pupillary dilation can provoke an acute attack. In patients with other forms of glaucoma, mydriasis may occasionally increase intraocular pressure. Therapy with sympathomimetic agents should be administered cautiously in patients with or predisposed to glaucoma, particularly narrow-angle glaucoma.

Chloral hydrate has a moderate potential interaction with Heart Disease.

Although continued use of chloral hydrate at therapeutic dosages has not been associated with deleterious effects on the heart, large doses may produce peripheral vasodilation, hypotension, arrhythmias, and myocardial depression. High dosages of chloral hydrate should be avoided in patients with severe cardiac disease.

The thonzylamine in dextromethorphan / phenylephrine / thonzylamine has a moderate potential interaction with Heart Disease.

Nasal decongestants that have thonzylamine should be used under physician supervision in patients with conditions such as high blood pressure, heart disease, diabetes, glaucoma, thyroid disease, and respiratory problems as emphysema or chronic bronchitis. Health care providers should outweighing the risks and the benefits of treatment in patients with these conditions.

The thonzylamine in dextromethorphan / phenylephrine / thonzylamine has a moderate potential interaction with High Blood Pressure.

Nasal decongestants that have thonzylamine should be used under physician supervision in patients with conditions such as high blood pressure, heart disease, diabetes, glaucoma, thyroid disease, and respiratory problems as emphysema or chronic bronchitis. Health care providers should outweighing the risks and the benefits of treatment in patients with these conditions.

The phenylephrine in dextromethorphan / phenylephrine / thonzylamine has a major potential interaction with Hyperthyroidism.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

Chloral hydrate has a major potential interaction with Liver Disease.

The use of chloral hydrate is contraindicated in patients with marked renal and/or hepatic impairment due to the potential for significant drug and metabolite accumulation. Chloral hydrate is metabolized by the liver and erythrocytes to the pharmacologically active compound, trichloroethanol (TCE), which has a plasma half-life of 8 to 12 hours. TCE is then metabolized further by both the liver and kidney to inactive substances that are slowly excreted in the urine. High plasma levels of chloral hydrate and TCE may produce respiratory depression and adverse cardiovascular effects such as peripheral vasodilation, hypotension, arrhythmias, and myocardial depression.

Chloral hydrate has a moderate potential interaction with Liver Disease.

In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.

Chloral hydrate has a moderate potential interaction with Peptic Ulcer.

Chloral hydrate may cause esophageal and gastric irritation. Oral use of chloral hydrate should be avoided in patients with esophagitis, gastritis, duodenitis, or peptic ulcer disease.

The phenylephrine in dextromethorphan / phenylephrine / thonzylamine has a major potential interaction with Pheochromocytoma.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

The phenylephrine in dextromethorphan / phenylephrine / thonzylamine has a moderate potential interaction with Prostate Tumor, Benign.

Sympathomimetic agents may cause or worsen urinary difficulty in patients with prostate enlargement due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.

Chloral hydrate has a moderate potential interaction with Pulmonary Impairment.

Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose. However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders. Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients. Appropriate monitoring and individualization of dosage are recommended.

The thonzylamine in dextromethorphan / phenylephrine / thonzylamine has a moderate potential interaction with Pulmonary Impairment.

Nasal decongestants that have thonzylamine should be used under physician supervision in patients with conditions such as high blood pressure, heart disease, diabetes, glaucoma, thyroid disease, and respiratory problems as emphysema or chronic bronchitis. Health care providers should outweighing the risks and the benefits of treatment in patients with these conditions.

Chloral hydrate has a major potential interaction with Renal Dysfunction.

The use of chloral hydrate is contraindicated in patients with marked renal and/or hepatic impairment due to the potential for significant drug and metabolite accumulation. Chloral hydrate is metabolized by the liver and erythrocytes to the pharmacologically active compound, trichloroethanol (TCE), which has a plasma half-life of 8 to 12 hours. TCE is then metabolized further by both the liver and kidney to inactive substances that are slowly excreted in the urine. High plasma levels of chloral hydrate and TCE may produce respiratory depression and adverse cardiovascular effects such as peripheral vasodilation, hypotension, arrhythmias, and myocardial depression.

Chloral hydrate has a moderate potential interaction with Respiratory Arrest.

Oral anxiolytic, sedative, and hypnotic agents may cause respiratory depression and apnea when given in high dosages or following acute overdose. However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders. Therapy with anxiolytic, sedative, and hypnotic agents should be administered cautiously in these patients. Appropriate monitoring and individualization of dosage are recommended.

The thonzylamine in dextromethorphan / phenylephrine / thonzylamine has a moderate potential interaction with Thyroid Disease.

Nasal decongestants that have thonzylamine should be used under physician supervision in patients with conditions such as high blood pressure, heart disease, diabetes, glaucoma, thyroid disease, and respiratory problems as emphysema or chronic bronchitis. Health care providers should outweighing the risks and the benefits of treatment in patients with these conditions.

Chloral hydrate has a moderate potential interaction with Urinary Retention.

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.

The thonzylamine in dextromethorphan / phenylephrine / thonzylamine has a moderate potential interaction with Urinary Tract Obstruction.

Nasal decongestants that have thonzylamine should be used under physician supervision in patients with conditions such as high blood pressure, heart disease, diabetes, glaucoma, thyroid disease, and respiratory problems as emphysema or chronic bronchitis. Health care providers should outweighing the risks and the benefits of treatment in patients with these conditions.